Becton Dickinson and Co (N:BDX)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | One Becton Drive FRANKLIN LAKES NJ 07417-1880 |
| Tel: | N/A |
| Website: | https://www.bd.com |
| IR: | See website |
| Key People | ||
| Thomas E. Polen Chairman of the Board, President, Chief Executive Officer | Pavan Mocherla Executive Vice President, President, Greater Asia | Christopher DelOrefice Chief Financial Officer, Executive Vice President |
| David B. Hickey Executive Vice President, President - Life Sciences Segment | Shana Carol Neal Chief People Officer, Executive Vice President | Antoine C. Ezell Executive Vice President, President, North America, Chief Marketing Officer |
| Michelle Quinn Executive Vice President, General Counsel | Richard Byrd Executive Vice President, President - Interventional Segment | Michael Garrison Executive Vice President, President - Medical Segment | Roland Goette Executive Vice President, President - EMEA |
| Business Overview |
| Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products. |
| Financial Overview |
| For the six months ended 31 March 2024, Becton Dickinson and Co revenues increased 4% to $9.75B. Net income applicable to common stockholders decreased 11% to $818M. Revenues reflect Interventional segment increase of 7% to $2.48B, Medical segment increase of 4% to $4.68B, Life Sciences segment increase of 1% to $2.59B, United States segment increase of 4% to $5.66B. Dividend per share increased from $1.82 to $1.90. |
| Employees: | 73,000 as of Sep 30, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $82,946M as of Mar 31, 2024 |
| Annual revenue (TTM): | $19,716M as of Mar 31, 2024 |
| EBITDA (TTM): | $4,880M as of Mar 31, 2024 |
| Net annual income (TTM): | $1,364M as of Mar 31, 2024 |
| Free cash flow (TTM): | $1,924M as of Mar 31, 2024 |
| Net Debt Last Fiscal Year: | $14,836M as of Mar 31, 2024 |
| Shares outstanding: | 290,391,793 as of Mar 31, 2024 |
| Index Membership: | S&P 500 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.